Literature DB >> 17382777

Vascular endothelial growth factor mediates hypoxic stimulated embryonic bladder growth in organ culture.

Berk Burgu1, Wanda E Medina Ortiz, Jolanta E Pitera, Adrian S Woolf, Duncan T Wilcox.   

Abstract

PURPOSE: Tissue hypoxia enhances embryonic angiogenesis at least in part by up-regulating vascular endothelial growth factor. Additionally, exogenous vascular endothelial growth factor-A enhances embryonic bladder explant growth. We hypothesized that developing bladders are hypoxic in vivo and oxygen tensions modulate explanted bladder growth by altering vascular endothelial growth factor-A expression.
MATERIALS AND METHODS: Embryonic day 14 mouse bladders were cultured in 20% O(2) or 3% O(2) atmospheres. Some cultures were supplemented with a vascular endothelial growth factor receptor 1/Fc chimera to block vascular endothelial growth factor bioactivity. After 6 days explant areas, DNA, protein, total cell numbers, and proportions expressing endothelial and smooth muscle markers were measured. Pimonidazole was administered to pregnant mice and hypoxia was sought in embryonic tissues by immunohistochemistry.
RESULTS: In vivo pimonidazole adducts and vascular endothelial growth factor-A immunolocalized to embryonic urothelium and bladders up-regulated total vascular endothelial growth factor-A between embryonic days 14 and 18. All growth parameters and vascular endothelial growth factor-A protein levels were enhanced in hypoxic vs normoxic culture. Addition of vascular endothelial growth factor receptor 1/Fc prevented this accelerated growth.
CONCLUSIONS: In vivo embryonic bladders are hypoxic and express vascular endothelial growth factor-A. In vitro, when oxygen tensions are manipulated, vascular endothelial growth factor-A protein positively correlates with the growth of whole explants as well as endothelium. Normal embryonic bladder development may be driven at least in part by hypoxic up-regulation of vascular endothelial growth factor-A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382777     DOI: 10.1016/j.juro.2006.12.011

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Mutations in HPSE2 cause urofacial syndrome.

Authors:  Sarah B Daly; Jill E Urquhart; Emma Hilton; Edward A McKenzie; Richard A Kammerer; Malcolm Lewis; Bronwyn Kerr; Helen Stuart; Dian Donnai; David A Long; Berk Burgu; Ozgu Aydogdu; Murat Derbent; Sixto Garcia-Minaur; Willie Reardon; Blanca Gener; Stavit Shalev; Rupert Smith; Adrian S Woolf; Graeme C Black; William G Newman
Journal:  Am J Hum Genet       Date:  2010-06-11       Impact factor: 11.025

2.  Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis.

Authors:  Katharine Tooke; Beatrice Girard; Margaret A Vizzard
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-17

3.  VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation.

Authors:  Marcia R Saban; Joseph M Backer; Marina V Backer; Julie Maier; Ben Fowler; Carole A Davis; Cindy Simpson; Xue-Ru Wu; Lori Birder; Michael R Freeman; Shay Soker; Robert E Hurst; Ricardo Saban
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-07

4.  VEGF induces sensory and motor peripheral plasticity, alters bladder function, and promotes visceral sensitivity.

Authors:  Anna P Malykhina; Qi Lei; Chris S Erickson; Miles L Epstein; Marcia R Saban; Carole A Davis; Ricardo Saban
Journal:  BMC Physiol       Date:  2012-12-19

5.  Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.

Authors:  Guangping Tai; Parisa Ranjzad; Fiona Marriage; Samrina Rehman; Helen Denley; Jill Dixon; Karen Mitchell; Philip J R Day; Adrian S Woolf
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.